Alliance Pharma plc provided financial guidance for 2018. For the period, the company expected revenues, on a statutory-reported basis to be £118.2 million, an increase of 16% on the prior year. Underlying profit before tax is expected to be in line with expectations.

For the year ended 31 December 2018, the company reported revenues on a 'see-through' basis for 2018 were up 22% on the prior year (up 23% on a constant currency basis) at approximately £124.0 million (2017: £101.6 million, restated following the adoption of IFRS 15). Excluding acquisitions, revenues increased 4% on the prior year (4% on a constant currency basis).